Form 4: RenovoRx Chief Medical Officer Increases Stake in Company
SEC Form 4 Filing
Ramtin Agah, Chief Medical Officer of RenovoRx, Inc., reports purchasing 26,000 shares of common stock in the open market.
Summary
- Ramtin Agah, the Chief Medical Officer of RenovoRx, Inc., has reported acquiring 26,000 shares of the company's common stock.
- The shares were purchased on April 8, 2025, at a weighted average price of $0.84 per share, with individual transactions ranging from $0.825 to $0.8499.
- Following the transaction, Agah directly owns 1,048,460 shares, which includes 975,000 shares previously held in a trust.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to insider buying, which often indicates confidence in the company's prospects. However, it's a single transaction and doesn't provide a comprehensive view.
Positives
- The Chief Medical Officer's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company insider believes the stock is undervalued.
Stakeholder Impact
- Shareholders may view the insider purchase positively.
Key Dates
| Date | Description |
|---|---|
| 01/19/2016 | Date of Mars16 Nevada Non-Grantor Trust |
| 04/08/2025 | Date of stock purchase transaction |
| 04/09/2025 | Date of Form 4 filing |
Keywords
RenovoRx, RNXT, insider trading, Ramtin Agah, Chief Medical Officer, stock purchase, Form 4, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.